General Comments / Chat, page-7743

Thanks for providing your view. It's definitely understandable and I'm sure his departure has cause others to pack up their bags as well (it certainly made me reconsider my view).

Nonetheless, it hasn't changed my thesis for a few reasons. The most important thing is that DT is still very much supportive of this company, and a believer in the product. Therefore, he certainly didn't leave because he believes Zantrene will be a dud, as if he did he would have sold out as well. He's made it pretty clear that this is the case on Facebook. Clearly he's left because of some other internal drama, and whilst he will be missed his presence is not necessary for the success of this company. End of the day, Zantrene is not dependent on DT

From my experience as well companies usually have to get through all or almost all of the clinical trial stage before they start receiving bids. Big Pharma tend to prefer products with proven efficacy and safety, as they add value to an acquisition through the economies of scale they have in commercialisation, not so much in clinical trials